药品注册申请号:016324
申请类型:NDA (新药申请)
申请人:LEGACY PHARMA
申请人全名:LEGACY PHARMA INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 IMURAN AZATHIOPRINE TABLET;ORAL 50MG Yes Yes AB 1968/03/20 Approved Prior to Jan 1, 1982 Prescription
002 IMURAN AZATHIOPRINE TABLET;ORAL 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None Approved Prior to Jan 1, 1982 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
审批日期提交号审批结论提交分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
1968/03/20 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
>>>补充申请<<<
审批日期提交号审批结论补充类别或审批类型审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/07/09 SUPPL-40(补充) Approval Labeling-Package Insert STANDARD
2018/12/20 SUPPL-39(补充) Approval Labeling-Package Insert STANDARD
2017/11/22 SUPPL-38(补充) Approval STANDARD
2014/05/21 SUPPL-36(补充) Approval Manufacturing (CMC) PRIORITY
2014/02/06 SUPPL-37(补充) Approval Labeling-Container/Carton Labels STANDARD
2011/05/24 SUPPL-35(补充) Approval Labeling-Package Insert UNKNOWN
2011/05/24 SUPPL-34(补充) Approval Labeling-Medication Guide UNKNOWN
2008/07/09 SUPPL-31(补充) Approval Labeling STANDARD
2005/07/26 SUPPL-30(补充) Approval Labeling STANDARD
2002/12/19 SUPPL-26(补充) Approval Labeling STANDARD
1994/08/30 SUPPL-11(补充) Approval Labeling
1992/10/26 SUPPL-22(补充) Approval Manufacturing (CMC)-Control PRIORITY
1992/07/09 SUPPL-20(补充) Approval Manufacturing (CMC) PRIORITY
1992/04/28 SUPPL-21(补充) Approval Manufacturing (CMC) PRIORITY
1989/10/17 SUPPL-16(补充) Approval Manufacturing (CMC)-Packaging PRIORITY
1988/05/24 SUPPL-14(补充) Approval Manufacturing (CMC)-Packaging PRIORITY
1988/04/18 SUPPL-17(补充) Approval Manufacturing (CMC)-Control PRIORITY
1987/02/26 SUPPL-13(补充) Approval Manufacturing (CMC)-Control PRIORITY
1981/04/13 SUPPL-10(补充) Approval Efficacy
1980/03/21 SUPPL-8(补充) Approval Manufacturing (CMC)-Control PRIORITY
1978/06/07 SUPPL-7(补充) Approval Manufacturing (CMC)-Control PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
>>>活性成分:AZATHIOPRINE; 剂型/给药途径:TABLET;ORAL; 规格:50MG; 治疗等效代码:AB<<<
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
016324 001 NDA IMURAN AZATHIOPRINE TABLET;ORAL 50MG Prescription Yes Yes AB Approved Prior to Jan 1, 1982 LEGACY PHARMA
074069 001 ANDA AZATHIOPRINE AZATHIOPRINE TABLET;ORAL 50MG Prescription No No AB 1996/02/16 AMNEAL
075252 001 ANDA AZASAN AZATHIOPRINE TABLET;ORAL 50MG Prescription No No AB 1999/06/07 AAIPHARMA LLC
075568 001 ANDA AZATHIOPRINE AZATHIOPRINE TABLET;ORAL 50MG Prescription No No AB 1999/12/13 RISING
077621 001 ANDA AZATHIOPRINE AZATHIOPRINE TABLET;ORAL 50MG Prescription No No AB 2007/03/15 ZYDUS PHARMS USA
208687 002 ANDA AZATHIOPRINE AZATHIOPRINE TABLET;ORAL 50MG Prescription No No AB 2020/03/27 ALKEM LABS LTD
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2025 DrugFuture->U.S. FDA Drugs Database